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Abstract Asp-474 in the first exoplasmic loop of the thyro-
tropin receptor (TSHR), which is conserved among all glyco-
protein hormone receptors, was mutated to Glu which is similarly 
charged but is longer by one methylene group and expressed in 
Cos-7 cells. Cells expressing this mutant receptor showed 
markedly impaired TSH- and TSAb (thyroid stimulating anti-
body)-stimulated cAMP responses with no effect on TSH 
binding affinity when compared with cells expressing a similar 
number of wild-type receptors. These results suggest the 
importance of Asp-474 in TSHR in receptor activation as 
demonstrated for LHR (lutropin receptor), but this, unlike LHR, 
is not due to the electrostatic interaction of this Asp residue with 
the oc-subunit Lys-91 of the hormone. 
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1. Introduction 
It has been suggested that the long extracellular domain of 
glycoprotein hormone receptors plays a major role in high-
affinity ligand binding [1-5]. However, how conformational 
changes in the t ransmembrane domain of the receptor result-
ing in G-protein coupling occur following ligand binding to 
the extracellular domain remains to be elucidated. 
It has been reported [6] that Asp-397 of the lutropin recep-
tor (LHR) at the junction of the second transmembrane helix 
and the first exoplasmic loop may interact with Lys-91 of the 
a-subunit of h C G (human choriogonadotropin) to evoke re-
ceptor activation. This hypothesis was suggested by the partial 
restoration of hormone-induced receptor activation by recip-
rocal mutagenesis of negatively charged Asp and positively 
charged Lys. As the a-subunit is common to all glycoprotein 
hormones and this Asp is uniquely conserved among all gly-
coprotein receptors, we hypothesized that this phenomenon 
might be common to all glycoprotein hormones and their 
receptors. 
To investigate the role of the corresponding Asp residue 
located at the junction of the second transmembrane helix 
and the first exoplasmic loop in the thyrotropin receptor 
(TSHR), we made substitution mutants at Asp-474 and func-
tional assays were performed using transfected cells. 
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2. Materials and methods 
2.1. Site-directed mutagenesis of TSHR 
Rat TSHR cDNA [7] was inserted into the EcoRl site of the 
M13mpl8 vector and oligonucleotide-mediated site-directed mutagen-
esis was used to generate clones with the desired mutation (T7GEN 
kit, US Biochemical, Cleveland, OH) [8,9]. Residue numbers were 
determined by counting from the methionine start site. Wild-type 
(WT) and mutant clones were inserted into the £coRI site of the 
SV-40-driven pSG5 vector (Strategene, La Jolla, CA). Mutations 
were confirmed by DNA sequencing of the final construct, and plas-
mid DNA was purified by CsCl-gradient ultracentrifugation. 
2.2. Transfection 
Cos-7 cells (-107 cells) were transfected by electroporation (Bio-
Rad, Richmond, CA) with 25 g of purified plasmid DNA containing 
a mutant or WT TSHR sequence [8,9]. When smaller amounts of 
TSHR DNA were used, the total amount of DNA per cuvette was 
kept constant by adding pSG5 vector DNA. To evaluate the trans-
fection efficiency, 0.1 |ig pSVGH was co-transfected with mutant or 
WT TSHR and/or pSG5 vector DNA. After electroporation, each 
batch of transfected cells was divided into aliquots for binding, 
cAMP and inositol phosphate assays. Cells intended for binding as-
says were suspended in Dulbecco's modified Eagle's medium contain-
ing 10% fetal calf serum, and transferred to 6-well plates (-5X10° 
cells/well). Cells for cAMP and inositol phosphate assays were sus-
pended in inositol-free medium supplemented with 10% fetal calf se-
rum and 2.5 |i.Ci/ml myo-[2-3H]inositol (DuPont-NEN, Boston, MA) 
and were transferred to 24-well plates (-105 cells/well). 
2.3. Assays 
Forty-eight hours after transfection, cells were washed with assay 
buffer (NaCl-free, Hanks' balanced salt solution containing 0.5% (w/ 
v) crystalline bovine serum albumin, 222 mM sucrose and 20 mM 
HEPES (2-[4-(2-hydroxyethyl)-1 -piperazinyl]ethanesulfonic acid)-
NaOH, pH 7.4) [8]. [125I]TSH binding was measured by incubating 
cells for 16 h at 4°C in 1 ml of assay buffer containing approximately 
80000 cpm [125I]TSH (30 U/mg, National Hormone and Pituitary 
Program; labeled to about 50 uCi/|ig by Hazelton Washington, Vien-
na, VA) and 0-10"7 M unlabeled TSH. Cyclic AMP and inositol 
phosphate production were measured concurrently by incubating cells 
for 1 h at 37°C in 0.2 ml of assay buffer containing 10 mM LiCl, 0.5 
mM IBMX (3-isobutyl-l-methylxanthine) and 0-10~7 M TSH or 
TSAb (thyroid-stimulating antibody) IgG from Graves' patients pu-
rified by Econo-Pac columns (Bio-Rad). Perchloric acid was added to 
each well, samples were centrifuged, aliquots of supernatant neutral-
ized with KOH and HEPES, and total cAMP in each aliquot was 
determined by 125I-radioimmunoassay (Eiken, Tokyo, Japan). Total 
inositol phosphates were measured by Dowex AG1-X8 anion ex-
change column chromatography (Bio-Rad). All assays were per-
formed at least in triplicate, on at least three separate occasions 
with different batches of cells, and always included control cells trans-
fected with WT TSHR and pSG5 vector DNA. Cos-7 cells transfected 
with pSG5 vector alone were not stimulated by TSH or TSAb, and 
did not exhibit specific [125I]TSH binding. The program LIGAND [10] 
was used to calculate KA and BmBX values for TSH binding. The GH 
concentration in the cultured media of cells used for the assays was 
determined by radioimmunoassay and was always within 15% of the 
mean. The density of live cells when the assays were performed varied 
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Fig. 1. cAMP accumulation in response to TSH in cells transfected with WT or mutant TSHR, or pSG5 vector DNA. Data are means ± SEM 
(«a3). Transfections were performed with 25 ug of DNA, except as noted for WT(2) in (A). 
by < 10% between wells transfected with WT TSHR and those trans-
fected with mutant constructs. Therefore, data were not normalized 
and were expressed as means ± SEM («>3). 
3. Results 
Cos-7 cells transfected with WT TSHR DNA (Fig. 1A) 
responded to TSH with an EC50 of about 2X10"
10 M and 
maximal response compared with its own basal cAMP level of 
about 6-fold. These cells showed 2.5-fold increase in basal 
cAMP level in the absence of agonist stimulation compared 
with cells transfected with pSG5 vector alone. In contrast, 
cells transfected with mutant D474E DNA (Fig. 1A) re-
sponded to TSH with an EC50 larger than 2XlO
- 8 M and 
maximal response at 10 - 7 M TSH compared to its basal level 
was 2.1-fold. These cells also showed an increased basal 
cAMP level of about 1.8-fold over that in control cells trans-
fected with pSG5 vector alone. Cos-7 cells transfected with 
mutant D474K, D474N or D474L DNA (Fig. IB) did not 
respond to TSH. These mutant transfected cells showed sim-
ilar basal cAMP levels to those in control transfectants. 
Table 1 shows Graves' IgG-stimulated cAMP responses in 
Cos-7 cells transfected with WT or mutant TSHR DNA. Cells 
with WT receptor responded well to Graves' IgG # 1 ; 2.3-fold 
at 0.5 mg/ml and 4.9-fold at 5 mg/ml. D474E mutant-trans-
fected cells showed a slight increase of 1.4-fold only at high 
concentration (5 mg/ml) of Graves' IgG #1 . This observation 
was consistent with those obtained with two other Graves' 
IgG samples. Cells transfected with D474K, D474N or 
D474L as well as pSG5 vector DNA showed no significant 
increase in cAMP levels by Graves' IgGs (P > 0.05 compared 
with normal IgG). 
The TSHR mediates inositol phosphate signals as well as 
those of cAMP [8,11]. Inositol phosphate levels were deter-
mined in aliquots of samples used for cAMP assays. None of 
the mutants showed increases in inositol phosphate levels in 
response to TSH or TSAb, whereas WT-transfected cells did 
but with less sensitivity (data not shown) as described previ-
ously [8,11]. 
Table 2 summarizes TSH binding parameters of cells trans-
fected with WT or mutant TSHR DNA. No TSH binding was 
detected in cells transfected with D474K, D474N or D474L 
DNA. Therefore, the lack of cAMP responses by stimulation 
with TSH and TSAb in these transfected cells may be attrib-
uted to disruption of the 3-dimensional structure or impaired 
membrane insertion. WT-transfected cells bound TSH with 
Kd of about 200 pM. D474E-transfected cells bound TSH 
with similar K&, but fimax of TSH binding was about 40% 
of that of WT-transfected cells. Decrease in receptor density 
on cells with mutant D474E receptor might have caused poor 
TSH- or TSAb-induced cAMP responses. Thus, we reduced 
the amount of WT DNA used for transfection from 25 to 2 ug 
(WT(2)). The Bmax of these cells was decreased to 37% of that 
of normal cells with WT receptors, a value similar to or less 
than that of D474E-transfected cells. 
However, these cells still responded well to TSH with EC50 
similar to that of normal WT-transfected cells and a maximal 
response of 6.4-fold (Fig. 1A, WT(2)). These observations for 
Table 1 
Cyclic AMP accumulation in response to IgGs from Graves' patients 
Mutant 
5 mg/ml normal IgG 
0.5 mg/ml Graves' IgG #1 
5.0 mg/ml Graves' IgG #1 
5.0 mg/ml Graves' IgG #2 
5.0 mg/ml Graves' IgG #3 
WT 
3.01 ±0.18 
6.93 ±0.02** 
14.71 ±0.62** 
9.26 ±0.78** 
7.55 ±0.19** 
D474E 
1.95±0.10 
1.89 ±0.09 
2.65±0.15* 
2.20 ±0.19* 
1.88±0.16 
D474K 
1.21 ±0.08 
ND 
1.41 ±0.01 
1.29 ±0.09 
1.34 ±0.09 
D474N 
1.32±0.15 
ND 
1.35 ±0.20 
1.2910.14 
1.2810.10 
D474L 
1.39 ±0.07 
ND 
1.4010.13 
1.3010.12 
1.2210.13 
pSG5 
1.2810.10 
1.3710.08 
1.3510.11 
1.2510.19 
1.2310.09 
cAMP accumulation (pmol/well), mean 1 SEM («>3). ND, not done. 
IgG. 
*P<0.05, compared with normal IgG. **P<0.01, compared with normal 
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Table 2 
TSH binding parameters of cells expressing mutant TSH receptor 
Mutant WT(25) WT(2) D474E D474K D474N D474L 
Kd (pM) 231 ±33 210± 16 194±29 UD UD UD 
Smax (%WT) 100 37 ± 5 40 ± 7 UD UD UD 
UD, undetectable. Data are expressed as means ± SEM of three independent experiments. 
WT(2) and D474E mutant, indicated that the impaired TSH-
and TSAb-stimulated cAMP responses in cells with D474E 
mutant receptors was not attributable to poor surface expres-
sion but to the mutation itself. 
4. Discussion 
Ji et al. reported [6] that (i) substitution of Asp-397 of the 
LHR to Lys resulted in complete loss of hCG-induced cAMP 
response without affecting hCG binding in transfected cells, 
and (ii) that cAMP responses in cells expressing WT LHR by 
mutant hCG with substitution of Lys-91 of the a-subunit 
were markedly decreased and insensitive, but the mutant 
hCG bound to WT LHR with similar affinity to WT hCG. 
(iii) When the hCG mutant was used with the Asp-394-to-Lys 
LHR mutant, the hCG-induced cAMP response was restored. 
However, substitution with other amino acids which elimi-
nated the counterionic nature failed to induce cAMP re-
sponses. Therefore, they concluded that Asp-397 of the 
LHR interacted with Lys-91 of ochCG [6]. 
The first aim of the present study was to examine whether 
the role of the corresponding Asp-474 in the TSHR is the 
same as that in the LHR. Cells expressing D474E mutant 
bound TSH with a similar K^ to that of WT but with a small-
er fimax- However, the most conservative substitution mutant 
D474E showed a poor TSH-cAMP response with an EC5o 
value more than 100-times higher than that of WT cells 
with a similar receptor density. This is in contrast to the 
corresponding Asp-to-Glu mutant of the LHR with only a 
3-fold increase in EC50 of hCG-induced cAMP activation 
[12]. The Asn, Arg and Lys LHR mutants showed almost 
completely abolished hCG-induced cAMP response without 
affecting hCG binding [12]. TSHR mutants D474K, D474N 
and D474L lost all TSHR functions including TSH binding, 
providing no informative evidence. Both Asp in WT and Glu 
in the mutant are negatively charged, and thus it is difficult to 
explain the electrostatic interaction with positively charged 
Lys residue of TSH. The present findings suggest a different 
mechanism of activation mediated by this hormone. Hydro-
gen bonding formed by the p-carbonyl group of Asp-474 
rather than electrostatic bonding might be important. How-
ever, D474N does not provide any information of TSHR 
structure/function as described above. The role of Asp-474 
in the TSHR may be similar to that of FSHR (follitropin 
receptor) rather than LHR; the corresponding Asp-405-to-
Glu mutant showed marked impairment of FSH-induced 
cAMP generation [13]. Investigation of substitution mutants 
of adjacent amino acids needs to be elucidated for detailed 
mechanism of receptor activation involving Asp-474. 
The other aim of the present study was to examine the 
hypothesis that TSAb but not TSH may activate Asp-474 
mutants because this Asp was postulated to interact with 
the a-subunit of glycoprotein hormone. However, this was 
not the case because D474E showed only a slight response 
to TSAb at higher concentrations, and decreases in TSH-
and TSAb-induced cAMP occurred in parallel. 
It is clear that Asp-474 is important for signal transduction 
but unclear and interesting how Asp-474 works. There are, 
however, at least two possible mechanisms: (a) Asp-474 may 
interact with agonist-extracellular domain complex to provoke 
conformational changes of transmembrane helices or (b) Asp-
474 may not be involved in direct interaction with agonist or 
the extracellular domain. However, the interaction of Asp-474 
with other portion(s) of the transmembrane domain may be 
necessary for the conformational change of the transmem-
brane domain during activation. Assuming an interaction be-
tween the agonist-extracellular domain complex and the trans-
membrane domain, direct interaction of the transmembrane 
domain may occur with (i) TSH after initial binding to the 
extracellular domain, (ii) the extracellular domain conforma-
tionally changed by TSH binding, or (iii) both. Multiple in-
teractions are suspected from the present findings and the 
data obtained from substitution mutation in the third exoplas-
mic loop [14]. 
In sum, D474E does not affect TSH binding affinity but 
does impair TSH- and TSAb-simulated cAMP responses. 
Asp-474 appears to be important for activation of the TSH 
receptor. The role of Asp-474 in receptor activation by TSH 
does not seem to be different from that by TSAb. 
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